Literature DB >> 4338767

Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis.

B Zbar, I D Bernstein, G L Bartlett, M G Hanna, H J Rapp.   

Abstract

Entities:  

Mesh：

Year:  1972        PMID： 4338767

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  41 in total

Review 1.  Non-specific immunotherapy with bacille Calmette-Guérin (BCG).

Authors:  A P van der Meijden
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

2.  Some perspectives on the transfer of cell-mediated immunity by immune-RNA.

Authors:  S Dray; D P Braun
Journal:  Mol Cell Biochem       Date:  1979-05-06       Impact factor: 3.396

3.  Stimulation of lymphocyte proliferation by killed mycobacteria and other bacterial species.

Authors:  A Bekierkunst
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

Review 4.  Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.

Authors:  Daher C Chade; Shahrokh F Shariat; Guido Dalbagni
Journal:  Int Braz J Urol       Date:  2009 Nov-Dec       Impact factor: 1.541

Review 5.  Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group.

Authors:  O Alfthan; K Jauhiainen; E Kaasinen; T Liukkonen
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

6.  Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.

Authors:  A P van der Meijden; P A Steerenberg; I M van Hoogstraaten; J A Kerckhaert; L M Schreinemachers; E J Harthoorn-Lasthuizen; A M Hagenaars; W H de Jong; F M Debruijne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

8.  Adjuvant BCG immunotherapy for malignant melanoma.

Authors:  A H Paterson; D J Willans; L M Jerry; J Hanson; T A McPherson
Journal:  Can Med Assoc J       Date:  1984-10-01       Impact factor: 8.262

9.  Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.

Authors:  R N Germain; R M Williams; B Benacerraf
Journal:  Am J Pathol       Date:  1976-12       Impact factor: 4.307

Review 10.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.